香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 交 所 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 GRAND BRILLIANCE GROUP HOLDINGS LIMITED 君 百 延 集 團 控 股 有 限 公 司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：8372） 本 公 告（君 百 延 集 團 控 股 有 限 公 司（「本 公 司」，連 同 其 附 屬 公 司 統 稱「本 集 團」 或「我 們」）各 董 事（「董 事」）願 就 此 共 同 及 個 別 承 擔 全 部 責 任）乃 遵 照 香 港 聯 交 所GEM證 券 上 市 規 則（「GEM上 市 規 則」）提 供 有 關 本 集 團 的 資 料。各 董 事 經 作 出 一 切 合 理 查 詢 後 確 認，就 彼 等 所 深 知 及 確 信：( ...

| 北京控股(00392) | 32.350 | 32.500 | 1.25% | | --- | --- | --- | --- | | 赤子城科技(09911) | 8.180 | 8.300 | 1.22% | | 交通银行(03328) | 6.860 | 7.010 | 1.20% | | 达芙妮国际(00210) | 0.455 | 0.490 | 1.03% | | 置富产业信托(00778) | 4.460 | 4.470 | 0.99% | | 网易－Ｓ(09999) | 166.100 | 173.200 | 0.99% | | 保诚(02378) | 85.000 | 85.650 | 0.94% | | 耀才证券金融(01428) | 7.640 | 8.730 | 0.92% | | 君百延集团(08372) | 0.113 | 0.120 | 0.84% | | 哈尔滨电气(01133) | 4.860 | 4.950 | 0.41% | | 康臣药业(01681) | 9.750 | 9.940 | 0.40% | | 电讯盈科(00008) | 5.320 | 5.400 | ...

Financial Performance - For the six months ended September 30, 2024, the group reported revenue of HKD 41,688,000, a slight increase of 0.93% compared to HKD 41,305,000 for the same period in 2023[3] - Gross profit for the same period was HKD 20,393,000, representing a gross margin of approximately 48.9%[3] - The net profit attributable to equity shareholders for the period was HKD 3,439,000, compared to a loss of HKD 87,000 in the previous year[3] - Basic and diluted earnings per share for the period were HKD 0.42, reflecting a significant improvement from the previous year[3] - Revenue from medical consumables reached HKD 30,014,000, up from HKD 26,497,000 in 2023, indicating a growth of about 13.5%[28] - The company reported a total of HKD 2,348,000 in other income for the six months ended September 30, 2024, compared to HKD 997,000 in 2023, reflecting a significant increase of approximately 135.5%[30] - The company's profit for the six months ended September 30, 2024, rose by approximately HKD 600,000 to HKD 3,400,000, attributed to government subsidies received amounting to approximately HKD 1,550,000[65] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 103,793,000, slightly down from HKD 104,195,000 as of March 31, 2024[5] - The group’s total liabilities decreased to HKD 8,985,000 from HKD 11,219,000, indicating improved financial stability[7] - The company’s equity attributable to shareholders increased to HKD 104,765,000 from HKD 103,326,000, showing a growth in shareholder value[7] - The company's total liabilities as of September 30, 2024, were HKD 20,266,000, compared to HKD 18,203,000 as of March 31, 2024, indicating an increase of approximately 11.3%[45] - Current liabilities decreased to approximately HKD 9 million from HKD 11.2 million as of March 31, 2024[67] Cash Flow and Management - The net cash generated from operating activities for the six months ended September 30, 2024, was HKD 623,000, compared to a net cash used of HKD 2,764,000 in the same period of 2023[12] - Cash and cash equivalents at the end of the period were HKD 57,884,000, compared to HKD 52,807,000 at the end of the same period in 2023, showing an increase of about 9.8%[12] - The company's total cash and cash equivalents decreased by HKD 2,104,000 during the period, compared to a decrease of HKD 8,278,000 in the same period of 2023, reflecting improved cash flow management[12] - The financing cash outflow for the repayment of lease liabilities was HKD 1,495,000, a decrease from HKD 2,051,000 in the previous year, indicating improved cash management[12] Dividends and Shareholder Information - The company has maintained a stable dividend policy, with a declared dividend of HKD 3,200,000 during the reporting period[10] - The company did not declare an interim dividend for the six months ended September 30, 2024, consistent with the previous year[39] - No interim dividend was declared for the six months ended September 30, 2024, consistent with the previous year[66] - The company reported a total of 8,000,000,000 authorized shares, with 800,000,000 shares issued and fully paid as of September 30, 2024[54] - The number of share options available for grant under the share option scheme increased to 71,940,000 shares, representing 8.99% of the total issued share capital as of September 30, 2024[55] Research and Development - Research and development expenses for the six months ended September 30, 2024, were approximately HKD 1,909,000, up from HKD 1,534,000 in the same period of 2023, indicating a growth of about 24.5%[35] Corporate Governance and Compliance - The company has adopted the corporate governance code and complied with all provisions, with some exceptions noted[90] - The roles of the chairman and CEO are held by the same individual, Ms. Huang, who is responsible for overall strategy and major decisions[92] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring proper oversight[93] - The audit committee reviewed the unaudited consolidated financial statements for the six months ending September 30, 2024, confirming compliance with applicable accounting standards[93] Market Outlook and Strategy - The group plans to continue exploring market expansion opportunities and enhancing product offerings in the upcoming periods[2] - The company maintains an optimistic outlook for the healthcare sector, driven by an aging population and increasing health awareness among Hong Kong citizens[59] - The company plans to further diversify its product offerings and enhance customer service to strengthen its position as a one-stop medical instrument solution provider[59] Risk Management - The company is closely monitoring foreign exchange risks, particularly with transactions settled in HKD, USD, or EUR, and is considering hedging measures[75]

Financial Performance - For the six months ended September 30, 2024, the company reported total revenue of HKD 41,688,000, an increase of 0.93% compared to HKD 41,305,000 for the same period in 2023[7] - The gross profit for the same period was HKD 20,393,000, reflecting a gross margin of approximately 48.9%[7] - The net profit attributable to equity shareholders for the six months was HKD 3,439,000, compared to a loss of HKD 87,000 in the previous year[7] - Basic and diluted earnings per share for the period were HKD 0.42, compared to HKD 0.00 in the same period last year[7] - The group reported a profit attributable to owners of HKD 3,439,000 for the six months ended September 30, 2024, up from HKD 2,846,000 in 2023, marking a growth of 20.8%[45] - The group’s profit increased by approximately HKD 600,000 from HKD 2,800,000 for the six months ended September 30, 2023, to HKD 3,400,000 for the same period in 2024, primarily due to government subsidies received[69] Revenue Breakdown - The group's revenue from medical consumables increased to HKD 30,014,000 in 2024 from HKD 26,497,000 in 2023, representing a growth of 18.9%[32] - Revenue from medical equipment decreased to HKD 9,677,000 in 2024 from HKD 12,811,000 in 2023, a decline of 24.5%[32] - Total revenue for the group was HKD 41,688,000 in 2024, compared to HKD 41,305,000 in 2023, reflecting a slight increase of 0.9%[32] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 103,793,000, slightly down from HKD 104,195,000 as of March 31, 2024[9] - As of September 30, 2024, the company's total assets minus current liabilities amounted to HKD 107,144,000, an increase from HKD 103,276,000 as of March 31, 2024, representing a growth of 3.4%[11] - The company's non-current liabilities, including lease liabilities, increased to HKD 2,516,000 as of September 30, 2024, compared to no non-current lease liabilities reported as of March 31, 2024[11] - Trade receivables decreased from HKD 15,414,000 as of March 31, 2024, to HKD 13,232,000 as of September 30, 2024, representing a decline of approximately 14.2%[49] - The net trade receivables after impairment provisions were HKD 11,814,000 as of September 30, 2024, down from HKD 13,943,000 as of March 31, 2024, indicating a decrease of about 15.3%[49] Cash Flow - The net cash from operating activities for the six months ended September 30, 2024, was HKD 623,000, compared to a cash outflow of HKD 2,764,000 for the same period in 2023[16] - The cash and cash equivalents at the end of the reporting period were HKD 57,884,000, a decrease from HKD 61,085,000 at the beginning of the period, representing a decline of 5.5%[16] - The company experienced a net cash outflow of HKD 2,104,000 in cash and cash equivalents during the reporting period, compared to a larger outflow of HKD 8,278,000 in the previous year[16] Corporate Governance - The company has confirmed that all information provided in the report is accurate and complete, with no misleading or fraudulent elements[6] - The board of directors is committed to ensuring compliance with GEM listing rules and has undertaken reasonable inquiries to verify the report's contents[6] - The company has complied with the GEM Listing Rules regarding the "Trading Musts" standards, with no violations reported by directors or employees[92] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring compliance with applicable accounting standards[97] - The company has maintained a governance structure that separates the roles of the chairman and CEO, although both roles are currently held by Ms. Huang[96] Shareholder Information - As of September 30, 2024, the company has a significant shareholder, B&A Success, holding 568,028,001 shares, representing 71.00% of the total equity[89] - Dr. Miao Yan Shun, spouse of Ms. Huang, is deemed to have the same equity interest as Ms. Huang, also holding 568,028,001 shares, equating to 71.00%[88] - Mr. Zhao Wen Wei holds 9,620,000 shares in the company, which accounts for 1.20% of the total equity[89] Employee and Operational Insights - The group employed 50 staff members as of September 30, 2024, with employee costs amounting to approximately HKD 10,300,000, an increase from HKD 9,400,000 for the same period in 2023[80] - Administrative and other operating expenses rose by approximately HKD 600,000 or 3.6%, from about HKD 16,200,000 for the six months ended September 30, 2023, to about HKD 16,800,000 for the same period in 2024[67] Future Outlook - The group remains optimistic about the healthcare industry due to the growing elderly population and increasing health awareness among Hong Kong citizens[63] - The group is seeking suitable investment opportunities to diversify its business and enhance returns for shareholders[63]

Financial Performance - For the fiscal year ending March 31, 2024, the company's revenue increased by approximately 6.8% to about HKD 81.9 million from approximately HKD 76.7 million for the previous year[10]. - Gross profit rose by approximately HKD 2.4 million or 6.1% to about HKD 41.9 million, while the gross profit margin slightly decreased from 51.5% to 51.2%[11]. - The group's profit increased from approximately HKD 7,600,000 for the year ended March 31, 2023, to approximately HKD 7,800,000 for the year ended March 31, 2024, representing an increase of about 2.63%[15]. - Income tax expense for the fiscal year was approximately HKD 400,000, a decrease from HKD 1.8 million in the previous year, attributed to tax planning strategies adopted by the company[13]. - The board declared an interim dividend of HKD 0.25 per ordinary share for the year ending March 31, 2024, down from HKD 0.4 in 2023[16]. Business Expansion and Strategy - The company established a joint venture to promote the development of autonomous mobile robot solutions in the healthcare sector, supporting business growth and expansion[9]. - A non-wholly owned subsidiary was set up in Macau with a registered capital of MOP 50,000, with an estimated investment cost of approximately HKD 300,000 to expand business in that region[9]. - The company is actively seeking suitable investment opportunities to diversify its business and enhance shareholder returns[6]. - The overall economic environment in Hong Kong is stabilizing post-COVID-19, contributing to the recovery of medical equipment revenues[10]. - The company is exploring market expansion opportunities in D regions, targeting a market penetration increase of E%[45]. Workforce and Employee Development - The group has expanded its workforce, hiring seven product representatives, two engineers, and other staff, increasing total employees to 46 from 41 in 2023[31]. - Overall attrition rate for the group increased to 32.2% in FY2024 from 19.5% in FY2023[177]. - The average training hours per employee decreased to 7.5 hours in FY2024 from 9.0 hours in FY2023[190]. - Approximately 40% of the middle management team is female, reflecting the company's commitment to diversity and equal opportunity[183]. - The group has implemented a transparent recruitment process based on skills, qualifications, and performance[180]. Corporate Governance - The company has adopted the principles and code provisions of the corporate governance code as per GEM Listing Rules Appendix C1, ensuring compliance with all provisions except for one[56]. - The board consists of six members, including the Chairperson and CEO, with a balanced composition in terms of age, gender, and tenure[63][67]. - The company emphasizes a culture of integrity and commitment to ethical standards, which is reflected in its training materials and employee handbook[57][58]. - The company has established three board committees: the audit committee, remuneration committee, and nomination committee, to enhance governance[72]. - The independent non-executive directors have confirmed their independence annually, aligning with GEM listing rules[68]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to sustainable development, integrating environmental, social, and governance (ESG) principles into its business strategy[131]. - The board reviews ESG performance at least annually and adjusts management methods as necessary[134]. - The group has conducted a materiality assessment to identify significant ESG issues, which will guide the preparation of the ESG report[140]. - The group has set a target to maintain or reduce the total harmless waste density from the FY2022 baseline of approximately 11.86 kg per million revenue by FY2030[160]. - The group encourages stakeholder feedback on its ESG policies and performance to enhance sustainable development efforts[149]. Risk Management and Compliance - The group has established risk management policies to identify, assess, and manage key business risks, with management responsible for overseeing these activities[106]. - The company has implemented a robust internal control system to manage risks and ensure compliance with regulatory requirements[67]. - The group has adopted a whistleblowing policy to promote compliance and ethical behavior, with no significant fraud or misconduct reported for the fiscal year ending March 31, 2024[108]. - The company has implemented an insider information disclosure policy to ensure timely and appropriate disclosure of sensitive information[112]. - The board believes that the group's risk management and internal control systems are effective and adequate, with no significant deficiencies identified[107].

香 港 會 計 準 則 第1號（修 訂 本） 附 帶 契 諾 的 非 流 動 負 債1 香 港 會 計 準 則 第1號（修 訂 本） 負 債 分 類 為 流 動 或 非 流 動1 香 港 詮 釋 第5號（經 修 訂） 呈 列 財 務 報 表 — 借 款 人 對 包 含 按 要 求 償 還 條 款 的 定 期 貸 款 的 分 類1 香 港 會 計 準 則 第7號 及 香 港 財 務 報 告 準 則 第7號 （修 訂 本） 供 應 商 融 資 安 排1 香 港 財 務 報 告 準 則 第16號（修 訂 本） 售 後 租 回 的 租 賃 負 債1 香 港 會 計 準 則 第21號（修 訂 本） 缺 乏 可 兌 換 性2 香 港 財 務 報 告 準 則 第10號 及 香 港 會 計 準 則 第28號（修 訂 本） 投 資 者 與 其 聯 營 公 司 或 合 營 企 業 之 間 的 資 產 出 售 或 注 資3 方 法1：就 香 港 會 計 準 則 第19.93(a)條 而 言，將 僱 員 長 服 金 福 利 之 預 計 抵 銷 金 額 入 賬 為 視 作 僱 員 供 款 方 法2：將 僱 主 強 積 金 供 款 及 ...

Financial Performance - The group's revenue for the six months ended September 30, 2023, was HKD 41,305,000, representing a 25.2% increase from HKD 33,024,000 in the same period of 2022[4] - Gross profit for the same period was HKD 20,324,000, up 17.9% from HKD 17,249,000 year-on-year[4] - The net profit attributable to equity shareholders for the six months was HKD 2,846,000, an increase of 11.8% compared to HKD 2,546,000 in the previous year[4] - Basic and diluted earnings per share increased to HKD 0.36 from HKD 0.32, reflecting a growth of 12.5%[4] - Revenue from medical equipment sales increased significantly to HKD 12,811,000, up 136.1% from HKD 5,423,000 in the previous year[20] - The cost of goods sold for the period was HKD 20,049,000, compared to HKD 14,607,000 in the prior year, reflecting a 37.0% increase[22] - Research and development expenses for the six months were HKD 1,534,000, up 37.8% from HKD 1,113,000 in the same period last year[22] - The income tax expense for the period was HKD 1,100,000, an increase of 62.3% from HKD 677,000 in the previous year[24] - Profit for the period increased by approximately HKD 200,000, from HKD 2,600,000 for the six months ended September 30, 2022, to HKD 2,800,000 for the same period in 2023[51] Assets and Liabilities - Total assets as of September 30, 2023, were HKD 100,559,000, slightly down from HKD 101,641,000 as of March 31, 2023[5] - Current assets net value increased to HKD 87,056,000 from HKD 85,752,000, indicating a positive trend in liquidity[7] - Cash and cash equivalents decreased to HKD 52,807,000 from HKD 61,085,000, a decline of 13.5%[9] - The group incurred a net cash outflow from operating activities of HKD 2,764,000 compared to a net inflow of HKD 9,105,000 in the previous year[9] - Contract liabilities increased to HKD 1,626,000 as of September 30, 2023, from HKD 760,000 as of March 31, 2023, indicating a rise in customer prepayments for medical instruments and services[31] - Trade receivables increased to HKD 21,329,000 as of September 30, 2023, compared to HKD 17,156,000 as of March 31, 2023, with a net trade receivables amount of HKD 19,798,000 after impairment provisions[33] - The company reported trade payables of HKD 5,634,000 as of September 30, 2023, a slight decrease from HKD 5,969,000 as of March 31, 2023[35] - The aging analysis of trade receivables showed that HKD 9,708,000 was within 30 days, while HKD 5,975,000 was overdue by more than 90 days as of September 30, 2023[34] Dividends and Shareholder Information - The group declared dividends of HKD 3,200,000 during the period, up from HKD 2,400,000 in the previous year[8] - The company declared an interim dividend of HKD 0.4 per share for the year ending March 31, 2023, up from HKD 0.3 per share in 2022, totaling HKD 3,200,000[26] - The company has a total of 800,000,000 issued and fully paid ordinary shares as of both September 30, 2023, and March 31, 2023[37] - The company has a total of 50,480,000 share options available for grant under its share option scheme as of September 30, 2023, representing 8.99% of the total issued share capital[38] Business Operations and Strategy - The company’s main business involves supplying medical instruments and providing related solutions, with all revenue generated from Hong Kong[20][17] - The company established a joint venture to develop autonomous mobile robotic solutions in the healthcare sector, aiming to support business growth[43] - A non-wholly owned subsidiary was established in Macau with a registered capital of MOP 50,000 to expand business operations, with an estimated investment cost of about HKD 300,000[43] - The company remains optimistic about the healthcare sector due to the increasing elderly population and rising health awareness among Hong Kong citizens[44] - The company is actively seeking strategic acquisition opportunities and has recruited two software engineers to enhance product development capabilities[67] - The company has established a new showroom and upgraded its IT infrastructure, including the implementation of an enterprise resource planning system[69] - The company has participated in various local and international trade exhibitions to increase market penetration and enhance market share[66] Employee and Operational Costs - The total employee costs, including director remuneration, were approximately HKD 9,400,000 for the six months ended September 30, 2023, compared to HKD 8,100,000 for the same period in 2022[64] - The company has expanded its workforce by hiring seven product representatives, two engineers, one warehouse staff, two R&D personnel, one administrative staff, two marketing personnel, and one accountant[66] Compliance and Governance - The company has complied with all provisions of the corporate governance code, except for the separation of the roles of Chairman and CEO, which are held by the same individual as of September 30, 2023[88] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, and has reviewed the unaudited consolidated financial statements for the six months ended September 30, 2023[90] Capital and Investment - The company had no significant capital commitments or major investments planned as of September 30, 2023[57] - The net proceeds from the share issuance amounted to approximately HKD 31.2 million, which is HKD 1.9 million lower than the estimated net proceeds of HKD 33.1 million disclosed in the prospectus[70] - As of September 30, 2023, the company has utilized HKD 3.0 million for general operating funds, with a remaining balance of HKD 2.9 million expected to be fully utilized by June 30, 2024[72] Technology and Development - The company has purchased new hardware and software for research and development purposes[68] - The company aims to develop autonomous mobile robotic solutions to alleviate healthcare workforce shortages, with HKD 4.0 million allocated for this initiative[72] - The company has redesigned and enhanced its website to include an e-commerce platform for retail customers[66] Financial Reporting and Standards - The company has not adopted any new accounting standards that have a significant impact on the financial statements for the current period[15] - The company reported no single customer contributing 10% or more to total revenue for the periods ended September 30, 2023, and 2022[19] - No purchases, sales, or redemptions of the company's listed securities were made by the company or its subsidiaries in the six months ended September 30, 2023[82]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 GRAND BRILLIANCE GROUP HOLDINGS LIMITED 君 百 延 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8372） 截 至2023年9月30日 止 六 個 月 之 中 期 業 績 公 告 君百延集團控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及 其附屬公司（統稱「本集團」）截至2023年9月30日止六個月之未經審核綜合 業 績（「中 期 業 績」）。本 公 告 載 列 本 集 團 截 至2023年9月30日 止 六 個 月 的 中 期 報 告 全 文，其 內 容 乃 根 據 香 港 聯 合 交 易 所 有 限 公 司（「香 港 聯 交 所」） GEM證 券 上 市 規 則（「GEM上 市 規 則」）的 相 關 披 露 規 定 而 編 製。中 期 業 績 已獲董事會及董事會轄下審核委員會審閱。 本業績公告於本公司網站(ww ...

香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應了解投資該等公司的潛在風險，並應經過 審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我 們」）各董事（「董事」）願就此共同及個別承擔全部責任）乃遵照香港聯交所GEM證券 上市規則（「GEM上市規則」）提供有關本集團的資料。各董事經作出一切合理查詢後 確認，就彼等所深知及確信：(1)本報告所載資料在各重大方面均屬準確及完整，並 無誤導及欺詐成分；(2)本報告並無遺漏其他事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 GRAND BRILLIANCE GROUP HOLDINGS LIMITED 君 百 延 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8372） 截 至 二 零 二 三 年 六 月 三 十 日 止 三 個 月 第 一 季 度 業 績 公 佈 君百延集團控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及 其附屬公司（統稱「本集團」）截至二零二三年六月三十日止三個月之未經 審 核 綜 合 業 績（「季 度 業 績」）。本 公 告 載 列 本 集 團 截 至 二 零 二 三 年 六 月 三十日止三個月的季度報告全文，其內容乃根據香港聯合交易所有限公 司（「聯交所」）GEM證券上市規則（「GEM上市規則」）的相關披露規定而編製。 季度業績已獲董事會及董事會轄下審核委員會審閱。 本 業 績 公 告 於 本 公 司 網 站(www.grandbrilliancegr ...